Introduction: Tourette syndrome (TS) is a chronic tic disorder characterized by both motor and vocal tics. The vast majority of patients present with co-morbid behavioral problems, especially tic-related obsessive-compulsive behaviors and attention-deficit and hyperactivity disorder. Evidence-based guidelines on the pharmacotherapy of TS have become available in recent years. Areas covered: The main purpose of this paper is to provide an overview of the current and emerging pharmacotherapeutic strategies for TS. A comprehensive search for the literature on the pharmacotherapy of tics was conducted using multiple databases (MEDLINE, Scopus, Web of Science, and Google Scholar), without date limits. Expert opinion: In consideration of the heterogeneity of the TS phenotypes, pharmacotherapy should be tailored to the individual patient. The choice of the pharmacological agent should take into account both the efficacy-to-tolerability ratio and the presence of co-morbid conditions. Evidence-based pharmacotherapy should aim at improving health-related quality life within a dynamic framework that typically requires active monitoring of the clinical presentation and reevaluation of the treatment intervention over time.

Cavanna, A. (2022). Current and emerging pharmacotherapeutic strategies for Tourette syndrome. EXPERT OPINION ON PHARMACOTHERAPY, 23(13), 1523-1533 [10.1080/14656566.2022.2107902].

Current and emerging pharmacotherapeutic strategies for Tourette syndrome

Cavanna A
2022

Abstract

Introduction: Tourette syndrome (TS) is a chronic tic disorder characterized by both motor and vocal tics. The vast majority of patients present with co-morbid behavioral problems, especially tic-related obsessive-compulsive behaviors and attention-deficit and hyperactivity disorder. Evidence-based guidelines on the pharmacotherapy of TS have become available in recent years. Areas covered: The main purpose of this paper is to provide an overview of the current and emerging pharmacotherapeutic strategies for TS. A comprehensive search for the literature on the pharmacotherapy of tics was conducted using multiple databases (MEDLINE, Scopus, Web of Science, and Google Scholar), without date limits. Expert opinion: In consideration of the heterogeneity of the TS phenotypes, pharmacotherapy should be tailored to the individual patient. The choice of the pharmacological agent should take into account both the efficacy-to-tolerability ratio and the presence of co-morbid conditions. Evidence-based pharmacotherapy should aim at improving health-related quality life within a dynamic framework that typically requires active monitoring of the clinical presentation and reevaluation of the treatment intervention over time.
Articolo in rivista - Review Essay
medications; pharmacotherapy; tic disorder; tics; Tourette syndrome;
English
1-ago-2022
2022
23
13
1523
1533
open
Cavanna, A. (2022). Current and emerging pharmacotherapeutic strategies for Tourette syndrome. EXPERT OPINION ON PHARMACOTHERAPY, 23(13), 1523-1533 [10.1080/14656566.2022.2107902].
File in questo prodotto:
File Dimensione Formato  
Cavanna-2022-Expert Opinion Pharmacoterapy-VoR.pdf

accesso aperto

Descrizione: Review
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 436.25 kB
Formato Adobe PDF
436.25 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/402076
Citazioni
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
Social impact